Aquaporin-4 (AQP4) is normally highly polarized to astrocyte end-feet surrounding blood vessels, critical for glymphatic CSF/ISF exchange. Early neurodegeneration triggers AQP4 depolarization and subsequent release within astrocyte-derived exosomes (ADEs) detectable in blood. Quantifying AQP4-enriched ADEs provides a peripheral window into neurovascular unit dysfunction before widespread astrogliosis becomes irreversible. The hypothesis is mechanistically compelling with evidence from AD mouse models showing AQP4 depolarization precedes amyloid deposition, but requires exosome isolation optimization and validation of the specific AQP4 fragment detectable in circulation.
Curated pathway from expert analysis
flowchart TD A["Neurodegeneration"] --> B["AQP4 Depolarization"] B --> C["Glymphatic CSF/ISF Exchange Failure"] B --> D["AQP4 Release in ADEs"] D --> E["Blood AQP4-Enriched ADE Detection"] C --> F["Amyloid Deposition Accumulation"] B --> G["Neurovascular Unit Dysfunction"] G --> H["Widespread Astrogliosis Onset"] A --> G E --> I["Early Neurovascular Biomarker"] H --> J["Irreversible Neurodegeneration"] F --> J I --> K["Therapeutic Intervention Window"] G --> F style A fill:#ef5350,color:#0d0d1a style B fill:#4fc3f7,color:#0d0d1a style C fill:#ef5350,color:#0d0d1a style D fill:#4fc3f7,color:#0d0d1a style E fill:#4fc3f7,color:#0d0d1a style F fill:#ef5350,color:#0d0d1a style G fill:#ef5350,color:#0d0d1a style H fill:#ef5350,color:#0d0d1a style I fill:#81c784,color:#0d0d1a style J fill:#ef5350,color:#0d0d1a style K fill:#81c784,color:#0d0d1a
No linked papers recorded for this hypothesis yet.
Median TPM across 13 brain regions for AQP4 from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for AQP4.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If astrocyte-derived exosomal AQP4 mislocalization predicts early glymphatic dysfunction, then exosomal AQP4 (brain-derived EVs, marked by GLT-1/SLC1A3) will show altered localization pattern (perinuc | In early AD/MCI (n≥80) vs age-matched controls, brain-derived EVs (GLT-1+) show 40-60% increase in perinuclear AQP4 localization by immunocytochemistry, which c | — no observation — | pending | 0.74 |
| If exosomal AQP4 mislocalization reflects glymphatic dysfunction, then correction of AQP4 polarization (e.g., by noradrenaline receptor antagonism) will restore exosomal AQP4 membrane localization and | In a proof-of-concept study, early AD patients receiving carvedilol (noradrenergic alpha-1/beta blocker, 12.5mg bid, 6 months) show restored exosomal AQP4 membr | — no observation — | pending | 0.68 |